New rapid diagnostic test for onchocerciasis elimination
Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination
This study is testing a new quick test for river blindness to see if it can help improve diagnosis and support efforts to eliminate the disease in Africa.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Bioaster Academic / other |
| Locations | 1 site (Yaoundé) |
| Trial ID | NCT06350851 on ClinicalTrials.gov |
What this trial studies
This study aims to develop and evaluate a new rapid diagnostic test for onchocerciasis, also known as river blindness, which is a major public health concern in Africa. The research will involve cross-sectional studies in Cameroon, where biological samples will be collected from individuals aged 18 and over who are mono-infected with Onchocerca volvulus, Loa loa, or Mansonella perstans. The goal is to improve the specificity of onchocerciasis diagnosis to facilitate better mapping and epidemiological assessments, ultimately supporting the World Health Organization's efforts to eliminate the disease. By addressing the limitations of existing diagnostic tools, this study seeks to enhance the accuracy of onchocerciasis detection in co-endemic regions.
Who should consider this trial
Good fit: Ideal candidates for this study include individuals aged 18 and over who are mono-infected with Onchocerca volvulus, Loa loa, or Mansonella perstans.
Not a fit: Patients who are pregnant, breastfeeding, or have taken antihelminthic treatment within the last six months will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and efficient diagnosis of onchocerciasis, improving treatment outcomes and supporting elimination efforts.
How similar studies have performed: Other studies have shown success in developing diagnostic tools for neglected tropical diseases, but this specific approach is novel in the context of onchocerciasis.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects informed of the objectives of the study and who signed a consent form * Subjects without filariasis (for control subjects), or * Subjects mono-infected with Onchocerca volvulus, or * Subjects mono-infected with Loa loa, or * Subjects mono-infected with Mansonella perstans or alternatively co-infected with Mansonella perstans and Loa loa Exclusion Criteria: * Pregnant or breast-feeding women * Subjects having taken antihelminthic treatment less than 6 months before the inclusion date
Where this trial is running
Yaoundé
- Higher Institute for Scientific and Medical Research — Yaoundé, Cameroon (Recruiting)
Study contacts
- Principal investigator: Joseph KAMGNO — ISM (Higher Institute for Scientific and Medical Research)
- Study coordinator: Marie KOENIG
- Email: marie.koenig@bioaster.org
- Phone: +33634452334
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.